Added to YB: 2025-11-21
Pitch date: 2025-10-16
ADPT [neutral]
Adaptive Biotechnologies Corporation
-9.18%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Market Cap
$2.1B
Pitch Price
$17.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-46.83
P/E
-25.97
EV/Sales
8.29
Sector
Life Sciences Tools and Services
Category
growth
Show full summary:
Aristotle Atlantic Core Equity Strategy Portfolio Holding: Adaptive Biotechnologies Corporation
ADPT (holding update): Q3 momentum in minimal residual disease (MRD) testing via flagship clonoSEQ for hematological cancers. Beat earnings expectations, raised FY guidance. ASP increases complementing accelerating volume growth in MRD business.
Read full article (1 min)